Cutaneous reactions to COVID-19 vaccines: A review

Wei, Tan See

doi:10.1016/j.jdin.2022.01.011

Cited by 31 publications

(56 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As suggested by previous studies, rash and urticaria have been the most studied systemic skin reactions related to COVID-19 vaccines [ 31 ]. Moreover, local injection site reactions were one of the most prevalent reactions [ 53 , 54 ]. After vaccination, the human body generates an immune response; meanwhile, the inflammation in the muscle at the injection site may occur [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Understanding the incidence pattern of cutaneous reactions is crucial for promoting COVID-19 vaccination. We aimed to report the global incidence pattern of, and factors associated with common cutaneous reactions related to COVID-19 vaccination in real-world settings. Methods We searched five databases (PubMed, Web of Science, Embase, CNKI, and Wanfang) from inception to May 13, 2022, for studies reporting the incidence of common cutaneous reactions related to COVID-19 vaccines in real-world settings. The outcomes were the systematic skin reactions (rash and urticaria) and the local injection site reactions (pain, swelling, redness, and erythema). We conducted random-effects meta-analyses and explored associated factors using multi-step statistical analyses. Results We included 35 studies and assessed 2 549 968 participants from 23 countries. The pooled incidence of overall systemic skin reactions was 3.8% (95% confidence interval (CI) = 2.4%-5.5%) with short duration (about one week). Specifically, the pooled incidence rates of rash and urticaria were 3.0% (95% CI = 2.1%-3.9%) and 1.1% (95% CI = 0.7%-1.5%), respectively. For overall local injection site reactions, the pooled incidence was 72.4% (95% CI = 65.7%-78.7%) with short duration (1 to 4.5 days). Except for local pain (72.2%, 95% CI = 65.3%-78.5%), other localized reactions had low incidence, including swelling (13.3%, 95% CI = 9.5%-17.7%), redness (11.5%, 95% CI = 5.7%-19.0%), and erythema (5.8%, 95% CI = 0.7%-15.4%). Geographically, different distribution patterns were observed for these reactions. Regarding associated factors, mRNA vaccines showed lower incidence of urticaria ( P < 0.001). Asia population showed higher incidence of urticaria ( P < 0.001). We observed lower incidence rates of overall local injection site reactions and pain among inactivated vaccines ( P < 0.001). We found no significant difference among reactions between the first and the second dose of vaccines. Conclusions We examined the global incidence pattern of common cutaneous reactions related to COVID-19 vaccination and found low incidence and short duration of systemic skin reactions and local injection site reactions (except for pain); discrepancies in these reactions were observed across different vaccine types. The cutaneous side effects related to COVID-19 vaccination do not seem to cause concern. Registration PROSPERO: CRD42021258012.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Moreover, local injection site reactions were one of the most prevalent reactions [ 53 , 54 ]. After vaccination, the human body generates an immune response; meanwhile, the inflammation in the muscle at the injection site may occur [ 53 ]. These responses can contribute to the adverse skin reactions [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Recent data 10 demonstrated that bullous eruptions accounted for 0.04% of reported skin reactions following COVID‐19 vaccination. All the reported cases in the review occurred after mRNA vaccination, with most occurring after the first dose.…”

Section: Discussionmentioning

confidence: 99%

Local bullous reaction as a cutaneous reaction after mRNA‐boosted vaccination in a post‐COVID patient

Kultawanich

Sampattavanich

2022

Clinical Case Reports

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The spectrum of symptomatic infection ranges from mild to critical with multiple severe complications. Many vaccines have been developed to prevent COVID‐19 disease, including an mRNA vaccine. Different adverse effects were reported as delayed large local reactions, swelling, erythema, urticarial, and morbilliform rashes. Among these, bullous reactions from the vaccine are considered rare. Here, we described a local bullous reaction after an mRNA booster vaccination in a post‐COVID patient.

show abstract

“…Hautveränderungen nach COVID‐19‐Impfung wurden in Einzelfallberichten beschrieben, jedoch gibt es derzeit nur unzureichend wenige kleinere Fallserien, Registerdaten und diverse Übersichtsarbeiten 10 . Eine im Januar 2022 veröffentlichte Übersichtsarbeit fasste sieben randomisierte kontrollierte Studien, eine registerbasierte Studie, eine prospektive Kohortenstudie, vier retrospektive Studien, 21 Fallserien und 41 Einzelfallberichte mit 48 740 gemeldeten Hautreaktionen bei 125 713 Patienten zusammen 11 . Da der Fokus einiger dieser klinischen Studien vor allem auf der Wirksamkeit des Impfstoffs lag, fehlten oft sowohl genaue Angaben zu kutanen Nebenwirkungen als auch detaillierte Informationen über die Studienteilnehmer.…”

Section: Introductionunclassified

Dermatologische Bewertung von Hautveränderungen nach COVID‐19‐Impfung – eine monozentrische Studie in Deutschland

Wang

Mathes

Claussen

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Hintergrund und Ziele Hautreaktionen nach COVID‐19‐Impfung werden in dieser Studie präzise mitsamt Schweregrad, Verlauf, Therapie, auslösender Impfstoffe, allergologischer Abklärung und der Verträglichkeit der Folgeimpfung untersucht. Patienten und Methodik 83 Patienten wurden in dieser monozentrischen Studie an einer dermatologischen Universitätsklinik untersucht. Ergebnisse Die Manifestationen (n = 93) gliederten sich in Sofort‐Überempfindlichkeitsreaktionen angelehnt an Soforttypallergien (n = 51; 54,8%), verzögerte Überempfindlichkeitsreaktionen angelehnt an Spättypallergien (n = 10; 10,8%), chronisch‐entzündliche Hauterkrankungen (n = 13; 14,0%), Reaktivierung einer latenten Herpesvirusinfektion (Pityriasis rosea und Herpes zoster; n = 9; 9,7%) und „Sonstige“ (n = 10; 10,8%). Sowohl nicht vorbekannte Hautreaktionen (76,3%) – vorrangig Sofort‐Überempfindlichkeitsreaktionen oder verzögerte Überempfindlichkeitsreaktionen – als auch eine Verschlechterung einer vorbekannten Hauterkrankung (23,7%) – meist chronisch‐entzündliche Hauterkrankungen – traten auf. Meist entwickelten sie sich innerhalb der ersten Woche (72,8%) und initial nach der ersten Impfung (62,0%). In 83,9% der Fälle erfolgte eine Therapie; in 19,4% sogar eine stationäre Behandlung. Eine Folgeimpfung führte bei 48,8% zum Wiederauftreten der gleichen Reaktion. Persistierende Reaktionen bis zum Zeitpunkt der letzten Vorstellung fanden sich in 22,6%, primär bei chronisch‐entzündlichen Hauterkrankungen. Eine allergologische Diagnostik wurde bei 15 Patienten (18,1%) durchgeführt; und zeigte negative Resultate. Schlussfolgerungen Eine durch COVID‐19‐Impfungen ausgelöste Aktivierung des Immunsystems kann insbesondere bei prädisponierten Patienten zu kutanen Reaktionen führen.

show abstract

Cutaneous reactions to COVID-19 vaccines: A review

Cited by 31 publications

References 71 publications

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

Local bullous reaction as a cutaneous reaction after mRNA‐boosted vaccination in a post‐COVID patient

Dermatologische Bewertung von Hautveränderungen nach COVID‐19‐Impfung – eine monozentrische Studie in Deutschland

Contact Info

Product

Resources

About